High Grade Nootropics Powder CAS 110958-19-5 Fasoracetam

Fasoracetam is a research chemical of the racetam family. It is a nootropic, and has been in clinical trials for vascular dementia and attention deficit hyperactivity disorder.
Fasoracetam appears to agonize all three metabotropic glutamate receptors and has improved cognitive function in rodent studies. It is orally available and is excreted mostly unchanged via the urine.

Originally known as NS-105, Fasoracetam is one of the newest nootropics on the market. Besides being the latest racetam to be discovered, it has some unique properties unlike any other racetam on the market. Let’s find out what makes this substance a truly unique nootropic, and why you should (or should not) add it to your stack.
One of the primary effects of Fasoracetam is the modulation of metabotropic glutamate receptors II and III (mGluR). mGlu receptors have been shown to be involved in synaptic plasticity and neuroprotection. In addition, LY354740, am mGlu2/3 agonist, has been shown to be effective in generalized anxiety disorder.
Fasoracetam is also the only racetam that significantly enhances cAMP formation and that has been shown to be effective in ADHD, particularly in individuals with glutamatergic gene variants[4], and a Phase III clinical trial is near completion.
Fasoracetam in animal studies has also shown to have antidepressant effects and to counteract learned helplessness, an avoidance behavior typically associated with depression. Fasoracetam, however, does not act on serotonin or other monoamines, and researchers think the antidepressant effect may stem from its ability to upregulate GABA-B receptors.
Generally speaking, Fasoracetam has shown to be more effective with chronic use, and, in the ADHD study, the peak effects in were felt in week five.

Main Benefits:

1. Improve Focus;

2. Improve memory;

3. For Alzheimer’s Disease;

4. For ADD and ADHS.

5. Anti-depression.

6. Improved Cognitive Processing

Dosage and Cautions:

Its antidepressant effects are most prominent at large doses and a standard dose has not yet been agreed upon. In human trials, 100mg a day has been given to subjects with no observed consequences, but some psychonauts use only 10mg a day sublingually.
This puts its potency level in line with nootropics like Noopept which are said to be 1000x stronger than Piracetam.